Purification of cyclotron-produced 203Pb for labeling Herceptin

Nuclear Medicine and Biology

Volumn 32, Issue 3, 2005, Pages 301-305

  Garmestani, Kayhan ^a   Milenic, Diane E ^a   Brady, Erik D ^a   Plascjak, Paul S ^b   Brechbiel, Martin W ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

203Pb; cyclotron; Herceptin; SPECT

Indexed keywords

ANTIBODY CONJUGATE; ION EXCHANGE RESIN; LEAD 203; THALLIUM; THALLIUM 203; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYCLOTRON; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG SCREENING; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOCHEMISTRY; RADIOIMMUNOASSAY; REACTION ANALYSIS; TECHNIQUE;

EID: 16844368023     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.11.004     Document Type: Article

References (23)

1. J.G. Jurcic, G. Sgouros, M.R. McDevitt, R.D. Finn, A.M. Ballangrud, and A.K.A. Klaus Targeted α-particle immunotherapy in humans Blood 100 2002 1233 1239
2. 211At Nucl. Med. Biol. 31 2004 357 364
3. M. Zalutsky, D. Reardon, G. Akabani, A. Friedman, H. Friedman, and J. Herndon Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: Phase I study Neuro-Oncol. 4 2002 S103
4. 213Bi for therapeutic applications Chem. Rev. 101 2001 2019 2036
5. M.R. McDevitt, D. Ma, L.T. Lai, J. Simon, P. Borchardt, and R.K. Frank Tumor therapy with targeted atomic nanogenerators Science 294 2001 1537 1540
6. G. Vaidyanathan, and M.R. Zalutsky Targeted therapy using alpha emitters Phys. Med. Biol. 41 1996 1915 1931
7. 212Pb-DOTA-AE1 J. Nucl. Med. 38 1997 1944 1950
8. 2- Radiochim. Acta 60 1993 1 10
9. J. Rotmensch, R.W. Atcher, R. Schlenker, J. Hines, D. Grdina, and B.S. Block The effect of the α-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy Gynecol. Oncol. 32 1989 236 239
10. J. Rotmensch, R.W. Atcher, J. Hines, D. Grdina, J. Schwartz, and M. Toohill The development of α-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma Am. J. Obstet. Gynol. 160 1989 789 797
11. 212Pb-labeled monoclonal antibody in the treatment of murine erythtoleukemia Int. J. Radiat. Oncol. Biol. Phys. 14 1996 609 616
12. 212Pb Nucl. Med. Biol. 27 2000 93 100
13. D.E. Milenic, M. Roselli, C.G. Pippin, M.W. Brechbiel, T.J. McMurray, and J.A. Carrasquillo In vivo evaluation of a lead-labelled monoclonal antibody using the DOTA ligand Eur. J. Nucl. Med. 25 1998 471 480
14. T.J. McMurry, M.W. Brechbiel, K. Kumar, and O.A. Gansow Convenient synthesis of bifunctional tetra-aza macrocycles Bioconjug. Chem. 3 1992 108 117
15. 111In labeled Herceptin™ Nucl. Med. Biol. 29 2002 599 606
16. M.D. Kozlova, V.I. Levin, A.B. Malinin, T.I. Kondratyeva, A.S. Sevastyanova, and N.V. Kurenko The production of carrier-free lead-203 Int. J. Appl. Radiat. Isot. 33 1982 553 555
17. C. Wu, O.A. Gansow, and M.W. Brechbiel Evaluation of methods for large scale preparation of antibody ligand conjugates Nucl. Med. Biol. 26 1999 339 342
18. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and A.J. Randall Protein measurement with the folin phenol reagent J. Biol. Chem. 193 1951 265 275
19. E. Dadachova, L.L. Chappell, and M.W. Brechbiel Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates Nucl. Med. Biol. 26 1999 977 982
20. R.H. Tom, L.H. Rutzky, and M.H. Jakstys Human colonic adenocarcinoma cells. Establishment and description of a new cell line In Vitro 12 1976 180 191
21. 203Pb via proton induced nuclear reactions on natural thallium Int. J. Appl. Radiat. Isot. 30 1979 85 95
22. P. Durbin Metabolic characteristics within a chemical family Health Phys. 2 1960 225 238
23. T.M. Quinn, J. Chen, W. Feng, M. Hylarides, and A. Fritzberg Peptide-targeted Pb-212/Bi-212 alpha radiation for melanoma therapy 225th Meeting of the American Chemistry Society, New Orleans, LA 2003 [NUCL 116]